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Effective transverse relaxivity of gadolinium-based contrast agents is often neglected in dynamic contrast-en-
hanced magnetic resonance imaging (DCE-MRI). Here, we assess time and tissue dependence of R2* en-
hancement and its impact on pharmacokinetic parameter quantification and treatment monitoring. Multiecho
DCE-MRI was performed at 7 T on mice bearing subcutaneous TOV-21G human ovarian cancer xenografts
(n  8) and on the transgenic adenocarcinoma of the mouse prostate (TRAMP) model (n  7). Subsequently,
the TOV-21G tumor-bearing mice were treated with bevacizumab and rescanned 2 days later. Pharmacoki-
netic analysis (extended Tofts model) was performed using either the first echo signal only (standard single-
echo DCE-MRI) or the estimated signal at TE  0 derived from exponential fitting of R2* relaxation (R2*-
corrected). Neglecting R2* enhancement causes underestimation of Gd-DOTA concentration (peak enhance-
ment underestimated by 9.4%–16% in TOV-21G tumors and 13%–20% in TRAMP prostates). Median Ktrans
and ve were underestimated in every mouse (TOV-21G Ktrans: 11%–19%, TOV-21G ve: 5.3%–8.9%; TRAMP
Ktrans: 8.6%–19%, TRAMP ve: 12%–21%). Bevacizumab treatment reduced Ktrans in all TOV-21G tumors af-
ter 48 hours. Treatment effect was significantly greater in all tumors after R2* correction (median change of
0.050 min1 in R2*-corrected Ktrans vs. 0.037 min1 in uncorrected Ktrans). R2* enhancement in DCE-
MRI is both time- and tissue-dependent and may not be negligible at 7 T in tissue with high Ktrans. This has
consequences for the use of Ktrans and other DCE-MRI parameters as biomarkers, because treatment effect
size can be underestimated when R2* enhancement is neglected.
INTRODUCTION
Dynamic contrast-enhanced (DCE) magnetic resonance imaging
(MRI) is used to characterize tissue vascularization by tracking
the distribution of an intravenously injected gadolinium (Gd)-
based contrast agent in tissue over the course of several minutes.
These paramagnetic contrast agents change the relaxation times
of tissue water protons, thereby influencing the signal intensity
in the images. As the net impact on signal intensity depends on
the concentration of a contrast agent in a given volume, the
serial magnetic resonance (MR) images provide qualitative or
quantitative information on contrast agent pharmacokinetics.
DCE-MRI is often employed in cancer diagnosis and treatment
monitoring, as neoangiogenesis in tumors creates tortuous and
leaky blood vessels that result in irregular contrast agent phar-
macokinetics (1). Moreover, it is frequently used to characterize
blood–brain barrier disruption (2, 3), myocardial perfusion (4),
or muscular perfusion (5).
Substantial efforts have been made in recent years to estab-
lish recommendations for DCE-MRI at the commonly used field
strengths of 1.5 T and 3 T (6-8). Several pharmacokinetic models
have been developed to extract quantitative information on
vascular structure and function (9). But the accelerating
adoption of high field scanners, to the point where MRI is
now regularly performed at 3 T or even 7 T, has caused
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This movement to higher fields affects DCE-MRI because, in
addition to enhancing the longitudinal relaxation rate (R1),
Gd-based contrast agents enhance transverse relaxation (R2*).
While this is exploited in dynamic susceptibility contrast (DSC)-
MRI, DCE-MRI data is acquired using heavily T1-weighted se-
quences and thus commonly assumed to be negligibly impacted
by R2* relaxation. This assumption is less valid at high field than
at low field because, in general, with increasing magnetic field
strength, effective transverse relaxivity (r2*) tends to increase,
while longitudinal relaxivity (r1) tends to decrease (10, 11).
Hence, R2* correction is especially important for preclinical
studies, which are often performed at a high-magnetic-field
strength of 7 T or higher. But even in the clinic, there is a trend
toward higher field strengths (12), which means that R2* cor-
rection may become more important in the future.
To address this problem, there is a growing use of multiecho
sequences for both DCE-MRI (13, 14) and DSC-MRI (15, 16) to
directly measure and account for contrast agent–induced R2*
enhancement. Several clinical and preclinical studies conducted
at various field strengths from 3 T to 7 T have investigated the
effect of R2* relaxation on the accuracy of measuring contrast
agent concentration in arterial blood (17, 18) and in the tissue of
interest (19-21) and have shown that R2* can significantly affect
quantitative DCE-MRI analysis (17-19, 21). However, the num-
ber of echoes required for reliable R2* correction and how the
impact of R2* relaxation on DCE-MRI parameter estimation
varies between cancer types have not yet been established.
Hence, the clinical significance of R2* correction in DCE-MRI
remains unclear.
The objective of this study is to address the time and tissue
dependence of the R2* effect on DCE-MRI parameter quantifi-
cation and its impact on cancer treatment monitoring. First, we
look at how the number of echoes used influences the precision
of R2* measurements. Then, we show that R2* is not linearly
dependent on contrast agent concentration but varies with time
and that the R2* dependence is different when comparing a
subcutaneous tumor xenograft model and a transgenic prostate
cancer model. Finally, we quantify the effect of R2* correction
on the pharmacokinetic parameters Ktrans, ve and vp, and illus-
trate how the effect of antiangiogenic treatment can be under-
estimated when R2* correction is neglected.
METHODOLOGY
Animal Models
All procedures and experiments involving animals were ap-
proved by the Norwegian Animal Research Authority (applica-
tion ID 9194) and performed according to the European
Convention for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes.
Eight female nude mice were injected subcutaneously in the
hind limb with 5  106 TOV-21G human ovarian cancer cells
(ATCC, Manassas, VA). Details of cell cultures and animal hous-
ing and handling can be found in Cebulla et al. (22) and Kim et
al. (23), respectively. Tumors were allowed to grow for 2–3
weeks before starting MRI experiments. MRI-measured tumor
volumes ranged from 55 to 203 mm3 (median  169 mm3).
Transgenic adenocarcinoma of the mouse prostate (TRAMP)
mice were bred in-house after obtaining a genetically modified
breeder pair from the C57BL/6 background from The Jackson
Laboratory, USA. Seven male mice were scanned when they
were of age between 22 and 34 weeks. Well-differentiated ade-
nocarcinoma commonly develops in the TRAMP model by age
18 weeks (24), with poorly differentiated tumors developing in
20%–30% of mice in our colony (25). Here, none of the mice
showed signs of large, poorly differentiated tumors on palpation
or in the images.
MRI
The TOV-21G tumors were imaged in vivo on a 7 T BioSpec
70/20 Avance III system (Bruker BioSpin, Ettlingen, Germany)
using an 86-mm transmit volume coil and a receive-only mouse
brain surface array coil. The mice were anesthetized with iso-
flurane (2% in 67% air/33% O2, 0.6 L/min), and respiration
rates were maintained at 60–70 breaths/min. A warm-air blower
was used to keep the animals’ body temperature at 37°C during
scanning.
The TRAMP mice were imaged in vivo on a 7 T Pharmascan
70/16 Avance III system (Bruker BioSpin) using a 72-mm trans-
mit volume coil and a 20-mm receive-only loop surface coil
with a dedicated preamplifier. The mice were anesthetized with
sevoflurane (2.5% in O2; 0.4 L/min), and respiration rates were
maintained at 50–60 breaths/min. A hot-water circulation sys-
tem was used to keep the animals’ body temperature at 37°C
during scanning.
To define tumor/prostate regions of interest (ROI), high-
resolution T2-weighted (T2w) images were acquired using a
rapid acquisition with relaxation enhancement sequence. To
compute baseline R1 maps, images were acquired using a rapid
acquisition with relaxation enhancement sequence with vari-
able repetition times (VTR). For DCE-MRI, a dynamic series of
images was acquired using a spoiled multiple-gradient echo
sequence with 10 echo times (TE). After the 10th baseline image,
a bolus of Gd-DOTA (Dotarem®, Guerbet, Villepinte, France) was
manually injected via the tail vein within 4 seconds (during the
11th repetition) at a dose of 0.1 mmol/kg. Pulse sequence pa-
rameters are provided in Table 1.
Immediately after imaging, the TOV-21G tumor-bearing
mice were treated with 5 mg/kg of bevacizumab (Avastin®,
Genentech, South San Francisco, CA), administered intraperito-
neally. Posttreatment scans using the same protocol were per-
formed 2 days later. In a previous study, we showed that this
regimen significantly reduced the blood volume, vascular den-
sity, and Ktrans of TOV-21G tumors (26).
Image Analysis
TOV-21G tumor ROIs and TRAMP prostate ROIs were manually
defined on the high-resolution T2w images and then down-
sampled to the resolution of the VTR and DCE-MRI images. For
comparison with normal tissue, ROIs were drawn in the muscle
adjacent to the TOV-21G tumors, and the same analysis was
performed. For each voxel in the ROIs, a 3-parameter monoex-
ponential decay model was fitted to the multiecho DCE-MRI
data (all 10 echoes):
S(TE, t)  S0(t)exp(R2
*(t)TE)  (t) . (1)
In addition, to examine the effect of TE on the R2* estima-
tion, nonlinear regression and simple log-linear calculations
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were performed using the first 5 echoes and the first 2 echoes,
respectively. Voxels for which the median R2 or the minimum R2
over the whole time-course was 0.75 or 0.5, respectively, were
excluded from further analysis.
DCE-MRI analysis was performed using either the first echo
signal only, which is equivalent to standard single-echo DCE-
MRI (uncorrected), or the model-estimated S(TE  0, t)  S0(t) 
(t) to account for R2* relaxation (R2*-corrected). The measured
(uncorrected) and estimated (R2*-corrected) signal–time curves
were converted to uncorrected and R2*-corrected Gd-DOTA
concentration–time curves by using the baseline R1 (R10) maps
computed from the VTR data and by assuming a linear relation-














TE (ms) 60 10 1.8, 3.8,
5.8,. . .,19.8
36 6 1.7, 3.5,
5.3,. . ., 17.9
TR (ms) 2000 250, 500, 1000, 2000,
4000, 8000
118 5500 350, 600, 1000, 1500,
3000, 6000
220
RARE Factor 16 2 n/a 8 2 n/a
FA (°) 90 90 40 90 90 56












Averages 8 1 1 5 1 1
Temporal Resolution (s) 144 330 4.96 495 300 10.56
Repetitions 1 1 200 1 1 100
FOV (mm) 14  14 25.5  19.2
Slices 5 23 9 9
Slice Thickness/Slice Gap (mm) 0.8/0.2 0.66/0
Abbreviations: TOV-21G, human ovarian cancer xenograft model; TRAMP, transgenic adenocarcinoma of the mouse prostate; RARE, rapid acquisition
with relaxation enhancement; ROI, region of interest; TR, repetition time; VTR, variable TR; T1, longitudinal relaxation time; MGE, multiple-gradient echo;
DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; TE, echo time; FA, flip angle; FOV, field of view.
Table 2. Precision of R2* Estimation as a Function of Number of Echoes
TOV-21G
R2* Coefficient of Determination Baseline R2* Coefficient of Variation
5-Echo 10-Echo 2-Echo 5-Echo 10-Echo
1 0.955 [0.900 0.981] 0.971 [0.949 0.983] 0.618 [0.390 1.002] 0.164 [0.114 0.233] 0.083 [0.056 0.114]
2 0.966 [0.917 0.987] 0.974 [0.953 0.987] 0.446 [0.254 0.763] 0.138 [0.093 0.204] 0.084 [0.055 0.117]
3 0.956 [0.901 0.982] 0.968 [0.944 0.983] 0.731 [0.449 1.265] 0.171 [0.110 0.257] 0.073 [0.047 0.109]
4 0.964 [0.920 0.985] 0.976 [0.959 0.987] 0.499 [0.324 0.771] 0.127 [0.092 0.180] 0.059 [0.044 0.080]
5 0.955 [0.906 0.980] 0.968 [0.948 0.981] 0.669 [0.437 1.047] 0.167 [0.110 0.239] 0.073 [0.048 0.103]
6 0.961 [0.906 0.985] 0.971 [0.950 0.984] 0.659 [0.362 1.098] 0.179 [0.107 0.268] 0.091 [0.057 0.133]
7 0.964 [0.917 0.986] 0.972 [0.951 0.985] 0.595 [0.343 1.068] 0.153 [0.099 0.235] 0.074 [0.050 0.105]
8 0.975 [0.944 0.989] 0.976 [0.960 0.986] 0.436 [0.286 0.717] 0.116 [0.080 0.165] 0.053 [0.036 0.070]
TRAMP
1 0.906 [0.787 0.958] 0.933 [0.887 0.961] 1.124 [0.726 1.962] 0.277 [0.200 0.372] 0.114 [0.086 0.154]
2 0.842 [0.631 0.934] 0.903 [0.827 0.944] 1.537 [0.967 2.755] 0.412 [0.311 0.576] 0.184 [0.137 0.244]
3 0.865 [0.698 0.941] 0.914 [0.849 0.950] 1.286 [0.838 2.213] 0.320 [0.239 0.419] 0.135 [0.104 0.173]
4 0.767 [0.432 0.913] 0.859 [0.733 0.926] 1.766 [1.073 3.409] 0.590 [0.391 1.993] 0.260 [0.182 0.369]
5 0.745 [0.377 0.903] 0.859 [0.723 0.925] 1.556 [0.931 2.952] 0.450 [0.331 0.742] 0.214 [0.151 0.297]
6 0.762 [0.392 0.912] 0.865 [0.729 0.931] 1.878 [1.121 3.744] 0.532 [0.370 1.989] 0.250 [0.172 0.358]
7 0.873 [0.710 0.944] 0.920 [0.863 0.953] 1.562 [0.870 3.257] 0.269 [0.181 0.391] 0.111 [0.078 0.156]
Median values and [25th and 75th percentiles] are reported for each animal.
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ship between R1 and concentration and a constant r1 of 3.2
mM1 s1 (27):
Gd-DOTA(t)(R1(t)  R10)/r1 (2)
Maps of the dynamic effective transverse relaxivity r2* of
Gd-DOTA were estimated assuming an analogous relationship:
r2*(t)(R2*(t)  R20
* )/Gd-DOTA(t) (3)
A biexponential arterial input function (AIF) was used for
pharmacokinetic (PK) modeling:
Cp(t)  D(A1exp(m1t)  A2exp(m2t)) (4)
where D is the administered contrast agent dose (here 0.1 mmol/
kg), A1  11.27 kg/L, m1  0.8 min-1, A2  4.23 kg/L, and m2 
Figure 1. R2* enhancement causes underesti-
mation of Gd-DOTA concentration. Median
R2*–time curve (R2* enhancement relative to
the median baseline value) for each TOV-21G
ovarian tumor xenograft (A) and transgenic ad-
enocarcinoma of the mouse prostate (TRAMP)
prostate (D). Corresponding median errors in
Gd-DOTA contrast agent concentration if calcu-
lated without correcting for R2* relaxation (B
and E). Median uncorrected and R2*-corrected
concentration–time curves for an example TOV-
21G tumor (C) and TRAMP prostate (F).
Figure 2. Gd-DOTA r2* relaxivity varies with
time and tissue type. Plots of median R2* (rela-
tive to the median baseline value) versus median
Gd-DOTA concentration parameterized by time
for the same TOV-21G ovarian tumor xenograft
(A) and TRAMP mouse prostate (B) in Figure 1, C
and F. Median r2* relaxivity–time curve (r2* 
R2*/[Gd-DOTA]) for each TOV-21G tumor (C)
and TRAMP prostate (D). Map of the r2* slope
from 30 seconds after Gd-DOTA administration to
the final time point for an example TOV-21G tu-
mor (E) and TRAMP prostate (F). Images of hema-
toxylin–eosin–saffron (HES)-stained sections illus-
trating the vastly different tissue architectures of a
TOV-21G tumor (G) and a TRAMP prostate (H).
Scale bars  300 m.
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0.0655 min-1. These coefficient values were determined by em-
pirically combining components of 2 population-averaged AIFs
from the literature. The peak amplitude (A1  A2) and m1 were
taken from a previous study that used similar manual bolus
administration and contrast agent concentration and dose, but
Gd-DTPA-BMA instead of Gd-DOTA (28). To account for the
difference in the clearance kinetics of the different contrast
agents, A2 and m2 were taken from another study that used
Gd-DOTA (13). This hybrid AIF gave better model fits than either
of the separate AIFs (see online supplemental Figure 1).
The extended Tofts model (29) was fitted to the uncorrected
and R2*-corrected concentration-time curves using constrained
(0  Ktrans  10, 0  ve  1, 0  vp  1) nonlinear least-squares
optimization to obtain uncorrected and R2*-corrected estimates
of Ktrans, ve, and vp. Voxels for which R2  0.5 were excluded
from further analysis. Voxels were classified as enhancing or
nonenhancing using Otsu’s method to threshold the relative
signal enhancement images 60 s after contrast agent arrival.
Nonenhancing voxels were also excluded from further analysis
(see online supplemental Table 1).
Statistical Analysis
The coefficient of determination (R2) was calculated for the
monoexponential fits of the first 5 and all 10 echoes for each
voxel and each acquisition time as a measure of goodness of fit.
The coefficient of variation of the 10 baseline R2* estimates
was calculated for each voxel. Assuming a temporally constant
baseline R2*, the coefficient of variation provides a measure of
the precision of estimating R2* using the first 2, first 5, and all 10
echoes.
A 2-way analysis of variance was performed to determine if
the effect of R2* on Tofts PK analysis (percent error in uncor-
rected parameter values with respect to R2*-corrected values)
varies with the Tofts parameter (Ktrans, ve, vp) and tissue type
(TOV-21G, TRAMP). Tukey honest significant difference post
hoc tests were performed on relevant pairs of parameters.
To assess the influence of the R2* effect on DCE-MRI-
measured response to bevacizumab treatment in TOV-21G tu-
mors, univariate paired t tests were performed on the pre- to
posttreatment changes in uncorrected vs R2*-corrected Tofts
parameter values. Paired t tests were also used to compare
median percent errors in Tofts parameter values before and after
treatment. The Benjamini–Hochberg procedure was used to cor-
rect for multiple testing.
RESULTS
More Echoes Give Better R2* Estimates
The R2 of the R2* exponential decay model [equation (1)] was
significantly greater (P  .001 for all animals, paired t test)
when all 10 echoes were used than when only 5 echoes were
used. However, the differences in median R2 were small for the
TOV-21G tumors, ranging from 0.08% to 1.7% (Table 2). The R2
for the TRAMP prostates was low, and the differences between
5- and 10-echo median R2 were large (3.0%–15.3%).
More importantly, the precision of R2* estimates, as mea-
sured by the coefficient of variation of the 10 baseline R2*
Figure 3. R2* enhancement af-
fects accuracy of dynamic contrast-
enhanced magnetic resonance im-
aging (DCE-MRI) parameters. Me-
dian Ktrans (A), ve (B), and vp (C)
values without (uncorr) and with
correction for R2* relaxation (R2*-
corr) for each TOV-21G ovarian
tumor xenograft (blue circles) and
TRAMP mouse prostate (red trian-
gles). Paired t tests were performed
to compare uncorrected and R2*-
corrected values, and P values
were corrected for multiple compar-
isons using the Benjamini–Hoch-
berg procedure. Median percent
errors (uncorrected vs R2*-cor-
rected) of Tofts parameter estimates
(D). A 2-way ANOVA and Tukey
honest significant difference post
hoc tests were performed to com-
pare the errors in different parame-
ters in different tissues (*P  .05,
**P  .001, ***P  .0001).
Multiecho DCE-MRI of Cancer Models
312 TOMOGRAPHY.ORG | VOLUME 5 NUMBER 3 | SEPTEMBER 2019
values, greatly increased with increasing number of echoes
(Table 2). For the TOV-21G tumors, the median coefficients of
variation were greater for 2-echo and 5-echo R2* estimates, by
5.3–10 times and 1.6–2.4 times, respectively, than for 10-echo
estimates. For the TRAMP prostates, the 2-echo and 5-echo
median coefficients of variation were 6.8–14 times and 2.1–2.4
times greater, respectively.
The absolute values of R2* were underestimated for high
values of R2* for 2-echo estimates compared to 10-echo esti-
mates, but the spread in 2-echo estimates was relatively low (see
online supplemental Figure 2A). For low values of 10-echo R2*
estimates, the spread in 2-echo R2* estimates was high, partic-
ularly for the TRAMP prostates. Compared with the 2-echo
estimates, the 5-echo R2* estimates were in better agreement
with the 10-echo R2* estimates.
R2* Enhancement Causes Underestimation of Gd-DOTA
Concentration
In TOV-21G tumors, R2*–time curves followed the general shape
of Gd-DOTA concentration–time curves—rapid initial enhance-
ment followed by a slower return toward baseline (Figure 1A).
This dynamic R2* enhancement resulted in a time-dependent
underestimation of the Gd-DOTA tissue concentration if the R2*
decay was not accounted for, with the error peaking at peak
concentration and then decreasing throughout the washout
phase (Figure 1, B and C). The median contrast agent concen-
tration error within each tumor ROI ranged from 9.4% to
16% at peak concentration and from 6.1% to 2.6% at the
end of the time series.
In comparison, the TRAMP prostates exhibited greater
initial enhancement and slower subsequent decrease in R2*;
in 2 TRAMPs, R2* actually continued to increase during
washout (Figure 1, D and F). Compared to TOV-21G tumors,
in TRAMP prostates, the greater and more prolonged R2*
enhancement resulted in greater concentration errors across
the time course (Figure 1E). The ROI-median contrast agent
concentrations were underestimated by between 13% and
20% at peak concentration and between 14% and 29% at the
end of the time series.
Figure 4. 2D histograms of un-
corrected versus R2*-corrected
DCE-MRI parameters. Pooled 2D
histograms of voxel-wise uncor-
rected versus R2*-corrected Tofts
parameter values from all TOV-
21G ovarian tumor xenografts
(A, C, E). Corresponding histo-
grams of the uncorrected parame-
ter errors versus R2*-corrected
values (B, D, F). Similar pooled,
voxel-wise histograms from all
TRAMP mouse prostates (G-L).
Histograms are color-coded by
normalized frequency.
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Gd-DOTA r2* Relaxivity Varies With Time and Tissue
Type
Although Gd-DOTA concentration, R2* enhancement, and con-
centration error were interrelated as expected, the relationships
were not simply linear, that is, the effective r2* relaxivity of the
contrast agent was not constant. The time-varying r2* is illus-
trated in plots of R2* enhancement (R2*) versus Gd-DOTA
concentration for an example TOV-21G tumor and TRAMP
prostate (Figure 2, A and B). There were 2 “branches” to these
curves, one corresponding to the initial intravascular/wash-in
phase (increase in Gd concentration with time) and the other to
the later extravascular/washout phase (decrease in Gd concen-
tration with time).
In both animal models, the initial r2* relaxivity was very
high when the contrast agent was presumably still mostly con-
tained in the vasculature (Figure 2, C and D). The ROI-median
initial r2* ranged from 197 to 717 s1mM1 in TOV-21G tumors
and from 419 to 825 s1mM1 in TRAMP prostates. Subse-
quently, r2* rapidly decreased after the first pass of the bolus and
as the contrast agent ostensibly extravasated into the tissue.
After this, the r2* behavior diverged in the 2 cancer models—on
average, r2* slowly decreased with time in the TOV-21G tumors,
but it slowly increased with time in the TRAMP prostates. This
difference between the 2 tissues is illustrated in Figure 2, E and
F, which shows maps of the r2* slope calculated from 30 seconds
post injection to the final time point. The r2* slope was generally
flat or negative in the TOV-21G tumor, whereas it was positive
in large areas of the TRAMP prostate.
R2* Enhancement Affects Accuracy of DCE-MRI
Parameters
The underestimation of Gd-DOTA concentration owing to R2*
enhancement led to errors in PK modeling (ie, differences be-
tween uncorrected and R2*-corrected parameter values; Figures
3–6). Furthermore, the time- and tissue-dependence of r2* re-
sulted in different effects on each Tofts parameter and on each
tissue type (P  .05, 2-way ANOVA; Table 3).
Ktrans was underestimated in both TOV-21G tumors and
TRAMP prostates, with the median percent error of uncorrected versus
R2*-corrected values ranging from 11% to 19% and 8.6% to 19%,
respectively (Figure 3, A and D). The Ktrans error was not significantly
different between the cancer models (P  .963; Table 4).
Ve was underestimated in TOV-21G tumors by 5.3% to 8.9%,
which was significantly less than the 12% to 21% underestimation
of ve in the TRAMP prostates (P  .019; Table 4, Figure 3, B and
D). In the TOV-21G tumors, R2* enhancement affected Ktrans
measurements significantly more than ve measurements (P 
.024); but in the TRAMP prostates, the effects of R2* enhance-
ment on Ktrans and ve were comparable (P  .924).
Interestingly, R2* enhancement resulted in overestima-
tion of vp in the TOV-21G tumors. There was a large variance
in vp errors (22% to 20%) in the TRAMP prostates (Figure
3, C and D).
Not only did Gd-DOTA-induced R2* enhancement have
different effects on different parameters in different tissue types,
the effect was not constant for a given parameter and tissue type
(Figure 4). This was most apparent with TOV-21G Ktrans, for
Figure 5. DCE-MRI parametric
maps for a TRAMP prostate.
Maps of Ktrans (A), ve (B), and vp
(C). Each panel shows maps of
the uncorrected values (left col-
umn), R2*-corrected values (center
column), and the error (right col-
umn). Maps are overlaid on the
high-resolution T2-weighted (T2w)
anatomical image. Nonenhancing
voxels and voxels where R2* or
Tofts model fitting were poor [R2*
median R2(t)  0.75 or R2* mini-
mum R2(t)  0.5 or Tofts R2 
0.5] are not shown on the maps.
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which there was a clear nonlinear relationship between the
uncorrected and R2*-corrected values (Figure 4, A and B). The
error was relatively small for low Ktrans, but it grew increasingly
larger for higher Ktrans. Similar trends were seen to lesser degrees
for Ktrans and ve in TRAMP prostates (Figure 4, G–J). As men-
tioned above, the median vp was overestimated in every TOV-
21G tumor; on the voxel level, for both TOV-21G and TRAMP,
overestimation occurred mostly for small vp ( 0.05), and un-
derestimation was more common for larger vp (Figure, 4, E–F
and K–L).
The number of echoes used for R2* correction also influ-
enced the DCE-MRI parameters (see online supplemental Figure
2, B–D). For the TOV-21G tumors, the 5-echo R2*-corrected
parameters approximated the 10-echo R2*-corrected ones fairly
well. However, high Ktrans were underestimated when only 2 or
5 echoes were used in comparison to 10 echoes. For the TRAMP
prostates, the differences between 5-echo and 10-echo R2*-
corrected parameters were larger than those for the TOV-21G
tumors.
R2* Enhancement Diminishes DCE-MRI-Measured
Treatment Effect Size
Median Ktrans was significantly reduced (P  .001 for both
uncorrected and R2*-corrected Ktrans) in the TOV-21G tumors 48
hours after treatment with bevacizumab (Figures 6 and 7). Me-
dian ve and vp were also reduced to a lesser extent (uncorrected
P  .086 and 0.075, respectively; R2*-corrected P  .070 and
0.086, respectively).
The magnitude of the treatment-induced reduction in Ktrans
was underestimated when R2* was not accounted for. This is
especially apparent when looking at the right tail of the pooled
histogram of all eligible voxels (based on the goodness of fit and
initial enhancement thresholds) from all tumor ROIs (Figure 7A).
The R2*-corrected 95th percentile Ktrans decreased by 0.127 	
0.042 min1 (mean 	 SD) after treatment, but the uncorrected
95th percentile Ktrans decreased by only 0.065 	 0.27 min1.
Thus, the uncorrected treatment effect size (Cohen’s dz  2.45)
was less than the R2*-corrected effect size (dz  3.07). This
was mainly owing to the underestimation of the high Ktrans
values before treatment. The median Ktrans was less affected by
R2* relaxation, and subsequently, the treatment effect on me-
dian Ktrans was underestimated to a lesser degree—the reduction
in R2*-corrected and uncorrected median Ktrans was 0.051 	
0.015 min1 (dz  3.36) and 0.037 	 0.012 min1 (dz 
3.12), respectively. Importantly, the treatment-induced changes in
both median and 95th percentile Ktrans were greater after R2* correc-
tion in each individual tumor (Figure 7B).
Compared with Ktrans, ve and vp were less affected by bevaci-
zumab treatment, and the treatment effect sizes were less affected
by R2* relaxation. For all 3 Tofts parameters, the magnitude of the
median percent error in parameter measurements owing to R2*
enhancement decreased after treatment (Figure 7C).
In the muscle, absolute Ktrans, ve and vp were lower and the
errors in uncorrected parameter estimates were smaller com-
pared with highly perfused areas of the tumor tissue and TRAMP
prostates (see online supplemental Figure 3). Changes in DCE-
parameters from before to after treatment were much lower in
Figure 6. DCE-MRI parametric maps for a TOV-
21G ovarian tumor xenograft. Maps of Ktrans (A),
ve (B), and vp (C). Each panel shows maps of the
uncorrected values (left column), R2*-corrected
values (center column), and the error (right col-
umn) before (top row) and 48 hours after (bottom
row) bevacizumab treatment (5 mg/kg). Maps
are overlaid on the high-resolution T2w anatomi-
cal image. Nonenhancing voxels and voxels
where R2* or Tofts model fitting were poor [R2*
median R2(t)  0.75 or R2* minimum R2(t)  0.5
or Tofts R2  0.5] are not shown on the maps.
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the muscle than in the tumor tissue and TRAMP prostates (see
online supplemental Figure 3).
DISCUSSION
Here, we showed that pharmacokinetic modeling of DCE-MRI
data is influenced by R2* relaxation, which is in agreement with
previous studies (17, 19).
One of the aims of the study was to investigate how many
echoes are necessary to provide reliable R2* estimates. We
showed that using more echoes for estimating R2* resulted in
higher R2* precision. However, the number of echoes necessary
for R2* correction depends on the study. A trade-off needs to be
made between the number of echoes and the temporal and
spatial resolution of the MR images. Although a high temporal
resolution allows for better PK modelling, a higher number of
echoes results in more accurate and precise R2* correction.
When the signal-to-noise ratio and image quality are good, 5 or
even 2 echoes may be sufficient. In this study, the TRAMP
prostates required a higher number of echoes for accurate R2*
computation than the TOV-21G tumors. This is likely because of
noise from flow and motion artifacts that were particularly
conspicuous in mice with full bladders as the contrast agent
flowed into the bladders over time. The artifacts and lower
temporal resolution (owing to the larger number of slices re-
quired to cover the tissue of interest) in the TRAMP data resulted
in poorer R2* and PK model fitting (see online supplemental
Table 1). These and other differences in data acquisition (scan-
ners, radiofrequency coils, pulse sequence parameters [Table 1])
confound direct comparisons between the TRAMP and TOV-21G
results.
Despite this, one very interesting finding of our study was
that the time dependence of R2* enhancement and r2* differed in
the 2 cancer models. In both models, an initial spike in R2* and
r2*, which corresponds to the first pass of the contrast agent
bolus, was observed. Then, the TOV-21G xenograft data be-
haved as expected, with R2* increasing and then decreasing as
the contrast agent extravasated from the blood vessels and was
cleared from the tumor tissue. During the washout phase, r2*
slowly decreased over time in the TOV-21G tumors. This indi-
cates that field inhomogeneities were reduced, as the Gd was
distributed throughout the extravascular–extracellular space of
the macroscopically homogeneous tumor tissue (Figure 2G). In a
few tumors, negative r2* values were measured at late time
points (Figure 2C). It has been shown through simulations and
phantom experiments that R2* is a nonmonotonic (quadratic)
function of contrast agent concentration and that this non-
monotonicity increases with field strength (30). It is possible that
R2* decreases below the baseline values at low contrast agent
concentration and compartmentalization. This may explain the
observed negative r2*.
Table 3. Results of 2-Way ANOVA Comparing R2* Effects Across Tissue Types and Tofts Parameters
Source Sum of Squares df Mean Square F-Statistic P-Value
Tissue Typea 312.909 1 312.909 9.800 .003
Parameterb 2360.776 2 1180.388 36.968 .001
Tissue Type  Parameter 333.915 2 166.958 5.229 .010
Error 1245.272 39 31.930
Total 4331.291 44
Abbreviation: df, degrees of freedom.
aTissue types, TOV-21G tumor and TRAMP prostate.
bParameters: Ktrans, ve, and vp.
Table 4. Post Hoc Comparisons of R2* Effects Between Tissue Types and Tofts Parameters Using Tukey Honest
Significant Difference Tests
Parameter Pair Lower 95% CI Estimated Difference Upper 95% CI P-Value
TOV-21G–TRAMP Ktrans 11.150 2.388 6.374 0.963
TOV-21G–TRAMP vea 1.106 9.868 18.630 0.019
TOV-21G–TRAMP vp 0.384 8.377 17.139 0.068
TOV-21G Ktrans–ve 17.783 9.319 0.854 0.024
TOV-21G Ktrans–vp 30.592 22.127 13.663 <0.001
TOV-21G ve–vp 21.273 12.809 4.344 0.001
TRAMP Ktrans–ve 6.112 2.937 11.986 0.924
TRAMP Ktrans–vp 20.411 11.362 2.313 0.007
TRAMP ve–vp 23.348 14.299 5.250 0.000
Abbreviation: CI, confidence interval.
aSignificant differences (P  .05) are highlighted in bold.
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Interestingly, the R2* and r2* behaved very differently in
the TRAMP prostates. After the initial peak, R2* decreased much
more slowly or even continued to increase during the washout
phase, corresponding to stable or increasing r2*. This could be
explained by the extravasated contrast agent becoming recom-
partmentalized in and around the glandular structures of the
prostate and increasing field heterogeneity (Figure 2H). While
the exact reasons for this divergent R2* behavior cannot be
elucidated here, it is important to note that the tissue structure
can play an important role in the contrast agent distribution and
the time dependence of r2* (31, 32). Thus, it would be difficult to
correct for R2* enhancement a priori.
In this study, we show that the uncorrected DCE-MRI pa-
rameters Ktrans and ve were significantly underestimated, which
is in line with previous studies (19, 21). Zhang et al. reported
median percent errors of larger than 20% for both Ktrans and ve
at 7 T (19), which is slightly larger than what we saw in our
study. Heilmann et al. also reported a significant underestima-
tion of Ktrans and slight underestimation of ve at 4.7 T (for R2*
correction of both AIF and concentration–time curve) (21). The
greater the Ktrans or ve and vp, the greater was their underesti-
mation without R2* correction. Our results also confirm the
findings of Zhang et al. that the error without R2* correction
increased for greater parameter values (19). Similar to our study,
the errors were particularly high for high Ktrans values, which
suggests that R2* correction is particularly important for tissues
with high Ktrans. Importantly, we found that the relationship
between corrected and uncorrected DCE-MRI parameters was
not linear, especially in Ktrans in the TOV-21G tumors. The
disproportionately large errors in regions of high Ktrans can lead
to underestimation of tumor heterogeneity (Figure 6A), which is
an important, clinically relevant prognostic factor (33). In less
Figure 7. R2* enhancement di-
minishes DCE-MRI-measured treat-
ment effect size. Pooled histo-
grams of voxel-wise uncorrected
(top row) and R2*-corrected (bot-
tom row) Tofts parameter values
(left to right: Ktrans, ve, vp) from
all TOV-21G ovarian tumor xeno-
grafts before (pre-Tx, blue) and
48 h after bevacizumab treat-
ment (post-Tx, red) (A). The solid
vertical lines mark the pre- and
post-Tx medians, and the dotted
vertical lines mark the pre- and
post-Tx 95th percentiles. The
treatment-induced changes in me-
dian (50th %tile) and 95th per-
centile uncorrected and R2*-cor-
rected Tofts parameter values for
each tumor (B). Paired t tests
were performed to compare un-
corrected and R2*-corrected
changes, and P values were cor-
rected for multiple comparisons
using the Benjamini–Hochberg
procedure. The median voxel-
wise percent errors in uncor-
rected Tofts parameter estimates
compared with R2*-corrected
estimates for each tumor pre- and
post-Tx (C). Paired t tests were
performed to compare the pre-
and post-Tx errors, and P values
were corrected for multiple com-
parisons using the Benjamini–
Hochberg procedure.
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perfused tissue such as muscle, R2* correction plays a less
important role.
In cancer treatment, response to chemotherapy and antivas-
cular therapies is often associated with a decrease in Ktrans from
baseline (34, 35). An important finding in our study was that the
therapeutic effect can be underestimated when non-R2*-cor-
rected DCE-MRI parameters are used for treatment monitoring.
Underestimation of treatment effect will be particularly large for
tumors or tumor regions with high Ktrans. This is significant
because a previous study conducted at 1.5 T has shown that
changes of around 44% for Ktrans and 41% for ve may be
necessary to indicate a treatment effect due to a relatively high
uncertainly of Ktrans in repeatability measurements (36). At
higher field strengths, R2* enhancement may further increase
uncertainty in DCE-MRI measurements, and correcting for it
would improve their reliability as biomarkers of treatment
response.
A limitation of this study was the use of a population-
averaged AIF from the literature. While individual AIFs might
provide more accurate DCE-MRI results, they are challenging to
acquire, and it has been shown that there is a high correlation
between DCE-MRI parameters derived using individual and
population-based AIFs (37). Previous studies have shown that it
is important to perform R2* correction on the AIFs, as noncor-
rected AIFs have been shown to overestimate Ktrans (17-19).
Hence, the use of R2*-corrected AIFs may have diminished the
underestimation of Ktrans reported here (19). In contrast, the AIF
obtained in our study was derived from 2 studies that measured
plasma Gd concentrations with MRI at 2.35 T (28) and with mass
spectrometry (13) and was thus less affected by R2* relaxation.
In conclusion, we showed that the R2* enhancement in
DCE-MRI is both time- and tissue-dependent. Furthermore, our
results suggest that R2* enhancement may significantly impact
pharmacokinetic analysis. As expected, acquiring more echoes
allows more accurate and precise measurement of R2*, but the
trade-off between better R2* estimation and higher temporal
resolution should be considered. In particular in tissue with high
Ktrans, R2* correction should be performed to avoid underesti-
mation. This has consequences for the use of Ktrans and other
DCE-MRI parameters as biomarkers in cancer diagnosis, because
underestimation of Ktrans can mislead prognosis and evaluation
of treatment response if R2* enhancement is neglected.
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